Pluristem Therapeutics Inc. (NasdaqCM: PSTI, TASE: PSTI/PLTR) is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, hematological disorders, or exposure to radiation.
Pluristem’s PLacental eXpanded (PLX) cells are placenta-derived, mesenchymal-like adherent stromal cells that are designed to be administered to patients without the need for tissue or genetic matching. These cells release soluble biomolecules, such as cytokines, chemokines and growth factors, which act in a paracrine or endocrine manner to facilitate healing of damaged tissues by stimulating the body’s own regenerative mechanisms. The Company’s proprietary, 3D expansion technology can be used to grow PLX cells in mass quantities with batch-to-batch consistency at Pluristem’s FDA, EMA and PMDA-approved, state-of-the art manufacturing facility.
Pluristem’s first product candidate is PLX-PAD, a cell therapy product for the treatment of tissues that have been damaged by muscle trauma or inflammation. Pluristem’s second cell therapy product in development, PLX-R18, is designed to treat hematological conditions including ARS, and insufficient hematopoietic recovery following hematopoietic cell transplantation (HCT).
Would you like to request an edit?
